Cargando…

Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands

BACKGROUND: Most randomised clinical trials typically exclude a significant proportion of asthma patients, including those at higher risk of adverse events, with comorbidities, obesity, poor inhaler technique and adherence, or smokers. However, these patients might differentially benefit from extraf...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Molen, Thys, Postma, Dirkje S., Martin, Richard J., Herings, Ron M. C., Overbeek, Jetty A., Thomas, Victoria, Miglio, Cristiana, Dekhuijzen, Richard, Roche, Nicolas, Guilbert, Theresa, Israel, Elliot, van Aalderen, Wim, Hillyer, Elizabeth V., van Rysewyk, Simon, Price, David B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869182/ https://www.ncbi.nlm.nih.gov/pubmed/27184175 http://dx.doi.org/10.1186/s12890-016-0234-0

Ejemplares similares

Erratum to: Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands
por: van der Molen, Thys, et al.
Publicado: (2016)

Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids
por: Postma, Dirkje S., et al.
Publicado: (2017)

Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study
por: Martin, Richard J, et al.
Publicado: (2014)

Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma
por: Gafar, Fajri, et al.
Publicado: (2018)

An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma
por: Burden, Anne, et al.
Publicado: (2017)

Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD
por: Postma, Dirkje S, et al.
Publicado: (2014)

Characteristics and first treatment dose of Dutch patients (12-60 years old) receiving prescriptions for asthma and initiating inhaled corticosteroids (ICS) therapy as either extra-fine (EF) ciclesonide or standard-particle (SP)-ICS
por: Van Eickles, Daniela, et al.
Publicado: (2015)

Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids
por: Sonnappa, Samatha, et al.
Publicado: (2017)

Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
por: Price, David B., et al.
Publicado: (2016)

Extrafine inhaled corticosteroid therapy in the control of asthma
por: Ivancsó, István, et al.
Publicado: (2013)

A self-rating scale for patient-perceived side effects of inhaled corticosteroids
por: Foster, Juliet M, et al.
Publicado: (2006)

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
por: Price, David B, et al.
Publicado: (2022)

Impact of multiple-dose versus single-dose inhaler devices on COPD patients’ persistence with long-acting β(2)-agonists: a dispensing database analysis
por: van Boven, Job FM, et al.
Publicado: (2014)

The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide?
por: van der Molen, Thys, et al.
Publicado: (2014)

Reassessing the Evidence Hierarchy in Asthma: Evaluating Comparative Effectiveness
por: Price, David, et al.
Publicado: (2011)

Dupuytren's contracture: a retrospective database analysis to determine hospitalizations in the Netherlands
por: Overbeek, Jetty A, et al.
Publicado: (2011)

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]
Publicado: (2022)

Development of a tool to recognize small airways dysfunction in asthma (SADT)
por: Schiphof-Godart, Lieke, et al.
Publicado: (2014)

Development, validity and responsiveness of the Clinical COPD Questionnaire
por: van der Molen, Thys, et al.
Publicado: (2003)

Inhaled corticosteroids in childhood asthma: the story continues
por: van Aalderen, Wim M. C., et al.
Publicado: (2010)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
por: Scichilone, Nicola, et al.
Publicado: (2014)

Inflammation and corticosteroid responsiveness in ex-, current- and never-smoking asthmatics
por: Telenga, Eef D, et al.
Publicado: (2013)

New Pharmacologic Perspectives in Pneumology: Beclomethasone-Formoterol Extrafine
por: Paggiaro, Pierluigi
Publicado: (2009)

Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease
por: van den Berge, Maarten, et al.
Publicado: (2012)

Completeness and Representativeness of the PHARMO General Practitioner (GP) Data: A Comparison with National Statistics
por: Overbeek, Jetty A, et al.
Publicado: (2023)

Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study
por: Singh, Dave, et al.
Publicado: (2017)

How to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze
por: van Aalderen, Wim M, et al.
Publicado: (2015)

Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
por: Singh, Dave, et al.
Publicado: (2014)

Otomastoiditis Caused by Mycobacterium abscessus, the Netherlands
por: van Ingen, Jakko, et al.
Publicado: (2010)

Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An In Silico Study
por: Usmani, Omar S., et al.
Publicado: (2021)

RETRACTED ARTICLE: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2008)

Retraction Note to: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2009)

Identification of frailty in primary care: accuracy of electronically derived measures
por: Swart, Karin MA, et al.
Publicado: (2023)

Relation Between Different Measures of Glycemic Exposure and Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes Mellitus: An Observational Cohort Study
por: van Wijngaarden, Rients P. T., et al.
Publicado: (2017)

Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes
por: Overbeek, Jetty A., et al.
Publicado: (2018)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
por: Singh, Dave, et al.
Publicado: (2020)

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation
por: Singh, Dave, et al.
Publicado: (2019)

Clinical effectiveness of liraglutide vs basal insulin in a real‐world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes
por: Overbeek, Jetty A., et al.
Publicado: (2018)

High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids
por: Paggiaro, Pierluigi, et al.
Publicado: (2016)

Pharmacology, particle deposition and drug administration techniques of intranasal corticosteroids for treating allergic rhinitis
por: Rollema, Corine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4n3oe3sc7677m7jvlibn2or1kd